Tyra Biosciences reports positive Phase 2 SURF302 results
Tyra Biosciences said initial Phase 2 SURF302 results were favorable and selected 60 mg once-daily as the potential dose for its planned registrational adjuvant strategy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.